| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
The primary target of N-Vanillyldecanamide is the transient receptor potential vanilloid type 1 (TRPV1) channel, which is involved in the perception of pain and temperature. By acting on TRPV1, it can modulate pain signaling pathways. Its effects are similar to those of capsaicin, but it may have distinct pharmacological properties.
|
|---|---|
| ln Vitro |
In vitro, N-Vanillyldecanamide has been shown to significantly reduce free radical length in alfalfa seedlings in a dose-dependent fashion. This suggests antioxidant activity. It also exhibits analgesic and anti-inflammatory properties in various in vitro models. Its activity at TRPV1 receptors can be assessed using calcium imaging or electrophysiological techniques in cells expressing TRPV1.
|
| ln Vivo |
Capsaicin
In vivo, N-Vanillyldecanamide has been studied for its analgesic and anti-inflammatory effects. As a capsaicinoid, it may produce similar effects to capsaicin, including pain relief and anti-inflammatory actions. Specific in vivo study protocols for N-Vanillyldecanamide are not extensively detailed in the available literature, but it is commonly used as a reference compound in pain research. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for N-Vanillyldecanamide typically involve radioligand binding studies using cells or membrane preparations expressing TRPV1 receptors. Competitive binding assays are performed using a radiolabeled capsaicin analog to determine the compound's affinity for TRPV1. Functional assays, such as calcium influx measurements, can also be used to assess its agonistic or antagonistic activity at the receptor.
|
| Cell Assay |
In vitro cellular assays for N-Vanillyldecanamide are conducted in cell lines expressing TRPV1 or in primary sensory neurons. Cells are treated with the compound, and calcium influx is measured using fluorescent indicators to assess TRPV1 activation. Cytotoxicity and cell viability assays can be performed to evaluate its safety profile. Its antioxidant activity can be assessed by measuring free radical scavenging in cell-based or cell-free systems.
|
| Animal Protocol |
In vivo animal studies for N-Vanillyldecanamide are typically conducted in rodent models of pain and inflammation. The compound is administered orally, intraperitoneally, or topically, and its analgesic effects are assessed using standard pain tests such as the hot plate test, tail flick test, or formalin test. Anti-inflammatory activity can be evaluated in models of acute or chronic inflammation.
|
| ADME/Pharmacokinetics |
D pharmacokinetic properties of N-Vanillyldecanamide indicate it has a molecular weight of 307.43 and a molecular formula of C18H29NO3. It is soluble in DMSO at concentrations up to approximately 250 mg/mL. For in vivo studies, it can be formulated in vehicles such as 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% saline. The powder should be stored at -20°C for up to 3 years.
|
| Toxicity/Toxicokinetics |
Toxicological information for N-Vanillyldecanamide is limited. As a capsaicinoid, it may cause irritation and burning sensations at high concentrations. Its safety profile would need to be carefully evaluated for therapeutic applications. Standard toxicology studies, including acute toxicity, skin irritation, and sensitization tests, would be required for clinical development.
|
| References | |
| Additional Infomation |
It has been reported that chili peppers (Capsicum annuum) contain n-vanillyldecanoamide, and relevant data is available. See also: Chili powder (partial).
N-Vanillyldecanamide is a capsaicinoid compound with analgesic and anti-inflammatory properties. It is also known as nonivamide. It is used in research as a tool for studying TRPV1-mediated pain pathways and as a reference compound for capsaicin-related studies. It is not approved for clinical use and is available from research chemical suppliers. |
| Molecular Formula |
C18H29NO3
|
|---|---|
| Molecular Weight |
307.43
|
| Exact Mass |
307.215
|
| CAS # |
31078-36-1
|
| PubChem CID |
169252
|
| Appearance |
White to off-white solid powder
|
| Density |
1.027g/cm3
|
| Boiling Point |
502.9ºC at 760mmHg
|
| Flash Point |
257.9ºC
|
| Index of Refraction |
1.511
|
| LogP |
4.548
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
22
|
| Complexity |
296
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
QLHTWDQJPOTDMV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H29NO3/c1-3-4-5-6-7-8-9-10-18(21)19-14-15-11-12-16(20)17(13-15)22-2/h11-13,20H,3-10,14H2,1-2H3,(H,19,21)
|
| Chemical Name |
N-[(4-hydroxy-3-methoxyphenyl)methyl]decanamide
|
| Synonyms |
Decanamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-; N-Vanillyldecanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~813.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (6.77 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2528 mL | 16.2639 mL | 32.5277 mL | |
| 5 mM | 0.6506 mL | 3.2528 mL | 6.5055 mL | |
| 10 mM | 0.3253 mL | 1.6264 mL | 3.2528 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
